Beilstein J. Org. Chem.2011,7, 29–33, doi:10.3762/bjoc.7.5
, quantification, and control of impurities in the drug substance and drug product are important parts of drugdevelopment for obtaining marketing approval. It is more challenging for an organic chemist to identify the impurities which are formed in very small quantities in a drug substance. Since most of the time
PDF
Graphical Abstract
Figure 1:
Sertindole (1), process related impurities and metabolites.
Beilstein J. Org. Chem.2010,6, No. 4, doi:10.3762/bjoc.6.4
systems and its potential in drugdevelopment has also been recognized [22].
The halogen bond (XB), whose terminology emphasizes the similarity with hydrogen bonding [23] can be schematically described by Y–X···A, where X is the XB donor atom (Lewis acid, electrophilic) and A is the XB acceptor atom
PDF
Graphical Abstract
Scheme 1:
The chemical structures of the salts 1–13.